Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Merck

143.79
-0.2100-0.15%
Post-market: 143.51-0.2800-0.19%19:33 EDT
Volume:8.29M
Turnover:1.19B
Market Cap:354.75B
PE:112.97
High:144.15
Open:143.85
Low:142.32
Close:144.00
52wk High:156.92
52wk Low:77.58
Shares:2.47B
Float Shares:2.47B
Volume Ratio:0.96
T/O Rate:0.34%
Dividend:3.36
Dividend Rate:2.34%
EPS(TTM):1.27
EPS(LYR):7.28
ROE:6.96%
ROA:11.87%
PB:8.46
PE(LYR):19.75

Loading ...

OverviewCompanyNewsFilings

Merck & Co - Keytruda Safety Profile Consistent with Previous Studies; no New Safety Signals Identified

THOMSON REUTERS
·
Jul 15

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Annexon Biosciences (ANNX) and Guardant Health (GH)

TIPRANKS
·
Jul 15

Zoetis Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 15

Movement Alert｜Merck Drops 3.03% in Regular Trading, Trading at $120.42

Market Focus
·
Jul 15

Dow's 159-point Drop Led by Losses in Shares of IBM, Merck

Dow Jones
·
Jul 14

Cosmos Health, Libytec Enter Distribution Deal for Diabetes Drug

MT Newswires Live
·
Jul 14

Merck is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 13

JPMorgan Adjusts Price Target on Merck to $140 From $135, Maintains Overweight Rating

MT Newswires Live
·
Jul 13

Merck & Co. Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Jul 11

Merck confirms FDA approves Keytruda combos with Padcev

TIPRANKS
·
Jul 11

FDA Approves Keytruda® (pembrolizumab) and Keytruda Qlex™ (pembrolizumab and Berahyaluronidase Alfa-pmph), Each with Padcev® (enfortumab Vedotin-ejfv), as Treatment Before and After Surgery for Adults with Muscle-invasive Bladder Cancer (mibc)

THOMSON REUTERS
·
Jul 11

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

MT Newswires Live
·
Jul 11

Merck's Keytruda Combination Wins Expanded FDA Approval for Muscle Invasive Bladder Cancer

MT Newswires Live
·
Jul 10

FDA approves Keytruda combos for certain muscle invasive bladder cancer cases

TIPRANKS
·
Jul 10

FDA Approves Pembrolizumab Combination for Muscle Invasive Bladder Cancer

Reuters
·
Jul 10

FDA: Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase Alfa-pmph Each with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer

THOMSON REUTERS
·
Jul 10

Berenberg Adjusts Price Target on Merck to $127 From $125, Keeps Hold Rating

MT Newswires Live
·
Jul 10

Merck & Co Inc : Berenberg Raises Target Price to $127 from $125

THOMSON REUTERS
·
Jul 10

Merck is Maintained at Equal-weight by Morgan Stanley

Dow Jones
·
Jul 10

Analysts Conflicted on These Healthcare Names: Cipher Pharmaceuticals (OtherCPHRF), Invivyd (IVVD) and Merck & Company (MRK)

TIPRANKS
·
Jul 09
More